15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Sutro Biopharma, 9 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $27.00 to $60.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $48.00 sits 100% above the current $24.05. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.46 next quarter toward $-6.88 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy9100%
Hold00%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Sutro Biopharma.
As of Jul, 9 of 9 firms rate STRO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
STRO EPS & revenue forecast
EPS · NEXT QUARTER
$-2.46
Range $-2.86 – $-2.10 · 3 analysts · -56% YoY
Next period, 3 analysts expect Sutro Biopharma to earn $-2.46 a share (range $-2.86 – $-2.10), versus $-5.57 a year earlier. Full-year consensus is $-7.80, growing to $-6.88 the year after.
REVENUE · NEXT QUARTER
$8.5M
Range $0 – $15.1M · 3 analysts · -12% YoY
Revenue is expected to reach $8.5M (range $0 – $15.1M), -12.4% year-over-year. Full-year consensus is $44.6M, rising to $31.6M next year.
Top analysts covering Sutro Biopharma
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on STRO.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Hold
$2.00-91.7% to target
Overall win rate
46%
+ Follow
#2
David Nierengarten
Wedbush · Rank #115
Buy
$60.00+149.5% to target
Overall win rate
41%
+ Follow
#3
Andrew Berens
Leerink Partners · Rank #167
Buy
$43.00+78.8% to target
Overall win rate
50%
+ Follow
#4
Andres Y. Maldonado
HC Wainwright & Co. · Rank #211
Buy
$50.00+107.9% to target
Overall win rate
38%
+ Follow
#5
TA
Tazeen Ahmad
B of A Securities · Rank #275
Sell
No targeton STRO
Overall win rate
41%
+ Follow
STRO stock forecast FAQ
What is STRO's average 12-month price target?+
The 8 analysts with a live target average $48.00 for Sutro Biopharma over the next 12 months, ranging from a $60.00 high to a $27.00 low.
Is STRO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 9 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for STRO?+
The Street-high target is $60.00 (Wedbush), and the Street-low is $27.00 (Wells Fargo). The average of all 8 active targets is $48.00.
How many Wall Street analysts cover STRO?+
9 analysts have an active rating on Sutro Biopharma, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering STRO?+
Among analysts who currently cover STRO, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Hold with a $2.00 target.
What is Sutro Biopharma's projected EPS for next quarter?+
The consensus estimate is $-2.46 per share (range $-2.86 – $-2.10) across 3 analysts. Full-year EPS is projected at $-7.80, rising to $-6.88 the following year.
How much revenue is Sutro Biopharma expected to report next quarter?+
Consensus revenue is $8.5M (range $0 – $15.1M). Full-year revenue is projected at $44.6M, growing to $31.6M next year.
Have analysts been upgrading or downgrading STRO lately?+
As of Jul, 9 of 9 firms rate STRO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their STRO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
